Literature DB >> 7332727

Theophylline pharmacokinetics in advanced age.

E J Antal, P A Kramer, S A Mercik, D J Chapron, I R Lawson.   

Abstract

1 Theophylline kinetics following a single oral dose were characterized and compared in non-institutionalized ambulatory elderly and young gender-matched control subjects. Study design stressed stringent, yet realistic, control of several external factors known to influence theophylline metabolism. 2 Plasma levels of total drug were significantly higher in the elderly only at early sampling times (0.5 and 1 h) and at 36 h, while unbound theophylline levels were significantly higher (P less than 0.05) at all sampling times resulting in a 45% greater AUC for unbound drug. 3 While no significant differences in volume of distribution (Vd) or overall plasma clearance were observed when calculations were based on total plasma theophylline, a 37% reduction in Vd (P less than 0.005) and a 30% reduction in overall plasma clearance (P less than 0.02) in the elderly became apparent when plasma protein binding was taken into account. 4 When urinary excretion patterns were compared, the elderly were found to have excreted a significantly higher fraction of the recovered dose as 1-methyluric acid (P less than 0.01) and a lower fraction as unchanged theophylline (P less than 0.02). A 47% reduction in the renal clearance of unbound theophylline (P less than 0.005) was also observed in the elderly. 5 Results were consistent with less viable metabolism and renal excretion pathways for theophylline elimination in the elderly and serve to reemphasize the importance of including an assessment of plasma protein binding in studies of drug disposition in the elderly.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7332727      PMCID: PMC1401974          DOI: 10.1111/j.1365-2125.1981.tb01282.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

2.  Rapid gas chromatographic determination of underivatized theophylline in whole blood.

Authors:  M Sheehan; P Haythorn
Journal:  J Chromatogr       Date:  1976-02-18

Review 3.  Clinical pharmacokinetics of theophylline.

Authors:  R I Ogilvie
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

4.  Microultrafiltration technique for drug-protein binding determination in plasma.

Authors:  V P Shah; S M Wallace; S Riegelman
Journal:  J Pharm Sci       Date:  1974-09       Impact factor: 3.534

5.  Intravenous theophylline therapy: nomogram guidelines.

Authors:  W J Jusko; J R Koup; J W Vance; J J Schentag; P Kuritzky
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

6.  Eliminating 1,7-dimethylxanthine interference from reversed-phase liquid-chromatographic analysis for theophylline.

Authors:  J R Miksic; B Hodes
Journal:  Clin Chem       Date:  1979-10       Impact factor: 8.327

7.  Theophylline metabolism by the rat liver microsomal system.

Authors:  S M Lohmann; R P Miech
Journal:  J Pharmacol Exp Ther       Date:  1976-01       Impact factor: 4.030

8.  Antipyrine disposition and liver size in the elderly.

Authors:  C G Swift; M Homeida; M Halliwell; C J Roberts
Journal:  Eur J Clin Pharmacol       Date:  1978-11-16       Impact factor: 2.953

9.  Effects of allopurinol on theophylline metabolism and clearance.

Authors:  J J Grygiel; L M Wing; J Farkas; D J Birkett
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

10.  Predisposing factors in adverse reactions to drugs.

Authors:  N Hurwitz
Journal:  Br Med J       Date:  1969-03-01
View more
  30 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  A study on the route of 1-methylurate formation in theophylline metabolism.

Authors:  C Bayar; I Ozer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Oct-Dec       Impact factor: 2.441

4.  Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage.

Authors:  R J Flanagan; A Johnston; A S White; P Crome
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

5.  Pharmacokinetics of pentopril in the elderly.

Authors:  A Rakhit; G M Kochak; V Tipnis; P Radensky; M E Hurley; R Williams
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

6.  The relationship between theophylline clearance and age in adult life.

Authors:  S H Jackson; A Johnston; R Woollard; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 7.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 8.  Theophylline poisoning. Pharmacological considerations and clinical management.

Authors:  P Gaudreault; J Guay
Journal:  Med Toxicol       Date:  1986 May-Jun

9.  The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women.

Authors:  K Groen; M A Horan; N A Roberts; R S Gulati; B Miljkovic; E J Jansen; V Paramsothy; D D Breimer; C F van Bezooijen
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

10.  Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.

Authors:  E Lunell; O Borgå; R Larsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.